HUTCHMED (China) Limited Sponsored ADR $HCM Shares Sold by M&G PLC

M&G PLC trimmed its stake in shares of HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) by 21.3% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 204,432 shares of the company’s stock after selling 55,185 shares during the quarter. M&G PLC’s holdings in HUTCHMED were worth $3,271,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the stock. ABN Amro Investment Solutions purchased a new position in shares of HUTCHMED in the 2nd quarter valued at about $962,000. Vanguard Personalized Indexing Management LLC raised its holdings in HUTCHMED by 23.2% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 15,490 shares of the company’s stock valued at $233,000 after acquiring an additional 2,916 shares in the last quarter. Tema Etfs LLC acquired a new stake in HUTCHMED in the second quarter valued at approximately $641,000. BNP Paribas Financial Markets lifted its stake in HUTCHMED by 19.7% in the second quarter. BNP Paribas Financial Markets now owns 25,046 shares of the company’s stock worth $377,000 after acquiring an additional 4,116 shares during the last quarter. Finally, Jane Street Group LLC grew its holdings in HUTCHMED by 128.0% during the 1st quarter. Jane Street Group LLC now owns 222,241 shares of the company’s stock worth $3,343,000 after acquiring an additional 124,771 shares in the last quarter. Hedge funds and other institutional investors own 8.82% of the company’s stock.

HUTCHMED Price Performance

HUTCHMED stock opened at $14.87 on Wednesday. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.65 and a quick ratio of 4.51. HUTCHMED has a fifty-two week low of $11.51 and a fifty-two week high of $19.50. The stock has a 50-day simple moving average of $14.44 and a 200-day simple moving average of $15.12.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on HCM. Weiss Ratings restated a “hold (c)” rating on shares of HUTCHMED in a report on Thursday, January 22nd. Jefferies Financial Group upgraded HUTCHMED to a “strong-buy” rating in a research note on Monday, January 19th. Finally, Wall Street Zen raised HUTCHMED from a “hold” rating to a “buy” rating in a research report on Sunday, November 16th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $20.88.

HUTCHMED Company Profile

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.